Log In
BCIQ
Print this Print this
 

CCP-08

  Manage Alerts
Collapse Summary General Information
Company Tris Pharma Inc.
DescriptionAn extended-release formulation of an undisclosed existing cough and cold product using Tris' OralXR+ extended release formulation technology
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationCough
Indication DetailsTreat cough and cold
Regulatory Designation
PartnerVernalis plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$89.0M

$5.0M

$84.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/10/2012

$89.0M

$5.0M

$84.0M

Get a free BioCentury trial today